Skip to main content

Advertisement

SpringerLink
Log in

Clinical features and prognostic factors of brain metastases from colorectal cancer: a single center experience

  • RESEARCH
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

The study aimed to investigate the clinical characteristics, prognostic factors, survival times, and therapy outcomes of brain metastases (BM) from colorectal cancer (CRC).

Methods

The clinical characteristics of 25 patients with BM from CRC were retrospectively analyzed. The time of the occurrence of BM after diagnosis of CRC was recorded. Meanwhile, the time from the occurrence of lung, bone, liver, and other extracranial metastases to the occurrence of BM was also recorded. We evaluate the time factors affecting the length of the occurrence of BM and the potential prognostic factors after BM diagnosis. The influences of patients undergoing surgery-based comprehensive treatment, radiotherapy-based comprehensive treatment, and co-medication were also assessed.

Results

In patients with BM from CRC, lung metastases (13/25) occurred at a higher frequency than liver metastases (8/25) and bone metastases (6/25). The median time to the development of BM was much shorter (3.7 vs. 25.3 months, p = 0.027), with the brain being the origin site for the metastasis. The median overall survival reached 9.9 months. The interval between diagnosis of BM and bone, liver, and lung metastasis remains 3, 6.5, and 11 months, respectively. The brain lesions of patients with BM alone had higher rates in supratentorial (88.9%), while those with extracranial metastasis had a 62.5% incidence of infratentorial metastasis. The difference was statistically significant (p < 0.05). The time of occurrence of BM in patients aged 67 years and younger was 16.1 and 30.1 months, respectively. The differences between them were statistically significant (p = 0.043). The BM time for left- and right-sided colon cancer were 26.5 and 7.8 months, representing a statistically significant difference (p = 0.015). The time to onset of BM for patients with and without the resection of primary lesions was 25.4 and 4.5 months. Statistically significant differences are shown (p = 0.007). Univariate analysis demonstrated that the prognosis of patients was related to the KPS score, the number of BM, the treatment methods, and the occurrence of lung metastasis (p < 0.05). The multivariate analysis revealed that the treatment modality and lung metastasis were independent prognostic factors for CRC patients with BM. Right-sided CRC patients with BM have a poor prognosis (8.1 vs. 10.2 months, p = 0.31). Although median survival time was not significantly different between patients with and without bevacizumab combination therapy, bevacizumab therapy is associated with a better survival time (9.9 vs. 7.1 months, p = 0.27).

Conclusion

Patients with left-sided CRC, especially those with lung metastases, are prone to brain metastases, and patients with brain metastases as the first metastatic site have a higher rate of supratentorial metastases. Young patients with right hemicolon cancer and patients who have not undergone primary lesion resection have a shorter time for the occurrence of BM. Patients with colorectal lung metastases, especially those young with right-sided CRC, require close imaging surveillance of BM. The prognosis of CRC patients with BM and lung metastases is poor, and comprehensive treatment based on surgery could significantly prolong patients’ survival time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Siegel RL, Wagle NS, Cercek A et al (2023) Colorectal cancer statistics, 2023. CA: Cancer J Clin 73(3):233–54. https://doi.org/10.3322/caac.21772

  2. Sedlak JC, Yilmaz ÖH, Roper J (2023) Metabolism and colorectal cancer. Ann Rev Pathol 18:467–92. https://doi.org/10.1146/annurev-pathmechdis-031521-041113

  3. Siegel RL, Mpller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA: Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708

  4. Cervantes A, Adam R, Roselló S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003

  5. Müller S, Köhler F, Hendricks A et al (2021) Brain metastases from colorectal cancer: a systematic review of the literature and meta-analysis to establish a guideline for daily treatment. Cancers 13(4). https://doi.org/10.3390/cancers13040900

  6. Chen PC, Yeh YM, Chu CT et al (2023) HER2 amplification in colorectal cancer with brain metastasis: a propensity score matching study. Eur J Cancer (Oxford, England: 1990) 181:62–9. https://doi.org/10.1016/j.ejca.2022.12.019

  7. Christensen TD, Palshof JA, Larsen FO et al (2017) Risk factors for brain metastases in patients with metastatic colorectal cancer. Acta oncologica (Stockholm, Sweden) 56(5):639–645. https://doi.org/10.1080/0284186x.2017.1290272

    Article  PubMed  Google Scholar 

  8. Chang Y, Wong CE, Lee PH et al (2022) Survival outcome of surgical resection vs. radiotherapy in brain metastasis from colorectal cancer: a meta-analysis. Front Med 9:768896. https://doi.org/10.3389/fmed.2022.768896

  9. Li W, Wang T, Zhu Y et al (2022) Brain metastasis from colorectal cancer: treatment, survival, and prognosis. Medicine 101(40):e30273. https://doi.org/10.1097/md.0000000000030273

  10. Li Y, Wu J, Liu F et al Single-fraction SRS and multiple-fraction SRT for brain metastases from colorectal cancer. Front Oncol 12:1060570. https://doi.org/10.3389/fonc.2022.1060570

  11. Liu X, Liu Q, Wu X et al (2023) Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: a systematic review network meta-analysis of randomized clinical trials. Cancer Med 12(3):2238–2247. https://doi.org/10.1002/cam4.5157

    Article  PubMed  Google Scholar 

  12. Cagney DN, Martin AM, Catalano PJ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 19(11):1511–1521. https://doi.org/10.1093/neuonc/nox077

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lei S, Ge Y, Tian S et al (2020) Colorectal cancer metastases to brain or bone and the relationship to primary tumor location: a population-based study. J Gastrointest Surg off J Soc Surg Aliment Tract 24(8):1833–1842. https://doi.org/10.1007/s11605-019-04308-8

    Article  PubMed  Google Scholar 

  14. Mjahed RB, Astaras C, Roth A et al (2022) Where are we now and where might we be headed in understanding and managing brain metastases in colorectal cancer patients? Curr Treat Options Oncol 23(7):980–1000. https://doi.org/10.1007/s11864-022-00982-0

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rades D, Nnguyen T, Janssen S et al (2020) An easy-to-use survival score compared to existing tools for older patients with cerebral metastases from colorectal cancer. Cancers 12(4). https://doi.org/10.3390/cancers12040833

  16. Lu X, Cai Y, Xia L et al (2019) Treatment modalities and relative survival in patients with brain metastasis from colorectal cancer. Biosci Trends 13(2):182–188. https://doi.org/10.5582/bst.2019.01044

    Article  PubMed  Google Scholar 

  17. Bergen ES, Scherleitner P, Ferreira P et al (2021) Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases. ESMO Open 6(3):100168. https://doi.org/10.1016/j.esmoop.2021.100168

  18. Quan J, Ma C, Sun P et al (2019) Brain metastasis from colorectal cancer: clinical characteristics, timing, survival and prognostic factors. Scand J Gastroenterol 54(11):1370–1375. https://doi.org/10.1080/00365521.2019.1686056

    Article  PubMed  Google Scholar 

  19. Gu XD, Cai YT, Zhou YM et al (2015) Prognostic factors and multidisciplinary treatment modalities for brain metastases from colorectal cancer: analysis of 93 patients. BMC Cancer 15:902. https://doi.org/10.1186/s12885-015-1933-2

  20. Patel AR, Neddzi L, Lau S et al (2018) Neoadjuvant stereotactic radiosurgery before surgical resection of cerebral metastases. World Neurosurg 120:e480-e7. https://doi.org/10.1016/j.wneu.2018.08.107

  21. Paix A, Antoni D, Adeduntan R et al (2017) Stereotactic radiation therapy of brain metastases from colorectal cancer: a single institution cohort. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 21(3):199–204. https://doi.org/10.1016/j.canrad.2017.01.010

    Article  CAS  PubMed  Google Scholar 

  22. Kim DY, Ryu CG, Jung EJ et al (2018) Brain metastasis from colorectal cancer: a single center experience. Ann Surg Treat Res 94(1):13–18. https://doi.org/10.4174/astr.2018.94.1.13

    Article  PubMed  Google Scholar 

  23. Chen X, Momin A, Wanggou S et al (2023) Mechanosensitive brain tumor cells construct blood-tumor barrier to mask chemosensitivity. Neuron 111(1):30-48.e14. https://doi.org/10.1016/j.neuron.2022.10.007

    Article  CAS  PubMed  Google Scholar 

  24. Łazarczyk M, Mickael ME, Sliba D et al (2023) The journey of cancer cells to the brain: challenges and opportunities. Int J Mol Sci 24(4). https://doi.org/10.3390/ijms24043854

  25. Kotecha R, Ahluwalia MS, Siomin V et al (2022) Surgery, stereotactic radiosurgery, and systemic therapy in the management of operable brain metastasis. Neurol Clin 40(2):421–436. https://doi.org/10.1016/j.ncl.2021.11.002

    Article  PubMed  Google Scholar 

  26. Perlow HK, Ho C, Matsui JK et al (2023) Comparing pre-operative versus post-operative single and multi-fraction stereotactic radiotherapy for patients with resectable brain metastases. Clin Transl Radiat Oncol 38:117–22. https://doi.org/10.1016/j.ctro.2022.11.004

  27. Xu M, Song K, Zhou Z et al (2022) Survival and prognostic factors in patients undergoing the resection of solitary brain metastasis from non-small cell lung cancer: a retrospective cohort study. J Thorac Dis 14(10):4113–24. https://doi.org/10.21037/jtd-22-1279

  28. Jin Z, Breen W, Jin R et al (2020) Multimodality management of brain metastasis from colorectal cancer. 38(4_suppl):204

  29. Majd N, Simon M, Wagman R et al (2022) A rare case of colon cancer metastasis to the brain anda brief review of its treatment and prognosis. Radiol Case Rep 17(3):696–699. https://doi.org/10.1016/j.radcr.2021.11.047

    Article  PubMed  Google Scholar 

  30. Cai J, Zheng J, Shen J et al (2020) A radiomics model for predicting the response to bevacizumab in brain necrosis after radiotherapy. Clin Cancer Res An Off J Am Assoc Cancer Res 26(20):5438–5447. https://doi.org/10.1158/1078-0432.Ccr-20-1264

    Article  CAS  PubMed  Google Scholar 

  31. Garci J, Hurwitz I, Sandler AB et al (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https://doi.org/10.1016/j.ctrv.2020.102017

  32. Finkelmeier F, You SJ, Waidmann O et al (2016) Bevacizumab in combination with chemotherapy for colorectal brain metastasis. J Gastrointest Cancer 47(1):82–88. https://doi.org/10.1007/s12029-015-9795-z

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to the patients and their families for supporting the study.

Funding

The study was funded by National Project for Clinical Key Specialty Development.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Peking University First Hospital, Beijing, 100034, China

    Zhao Gao, Xuan Jin & Shikai Wu

Authors
  1. Zhao Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shikai Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The first draft of the manuscript was written by Zhao Gao, and all authors commented on previous versions of the manuscript. Shikai Wu and Xuan Jin conceived of the review and edited the manuscript. Zhao Gao collected and analyzed the data. Xuan Jin analyzed the data and drafted the article. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shikai Wu.

Ethics declarations

Ethics approval

This study has been approved by the Ethics Committee of the Peking University First Hospital.

Consent to participate

Not required.

Consent for publication

Not required.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, Z., Jin, X. & Wu, S. Clinical features and prognostic factors of brain metastases from colorectal cancer: a single center experience. Int J Colorectal Dis 38, 198 (2023). https://doi.org/10.1007/s00384-023-04451-4

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00384-023-04451-4

Keywords

Search

Navigation